ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Recurrent Ovarian Carcinoma Management

DOI:10.31550/1727-2378-2020-19-1-62-68
Bibliography link: Guseinov K.D., Berlev I.V., Belyaev A.M., Urmancheeva A.F., Gorodnova T.V., Kireeva G.S., Yakovleva M.G., Shikhzadaeva M.G. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Recurrent Ovarian Carcinoma Management. Doctor.Ru. 2020; 19(1): 62–68. (in Russian) DOI: 10.31550/1727-2378-2020-19-1-62-68
4 February 11:03

Study Objective: to analyse management outcomes of patients with recurrent ovarian carcinoma (OC) using hyperthermic intraperitoneal chemoperfusion (HIPEC).

Study Design: prospective study.

Materials and Methods. Therapy results for two groups of patients were compared: group I (study group) — 92 women with first OC relapse in August 2006 – October 2013 were treated with combined modality treatment (repeated HIPEC and chemotherapy); group II (control group) — 80 patients with diagnosed first OC relapse who underwent system chemotherapy following debulking intervention.

Study Results. There were no intraoperative complications resulting in severe body dysfunction. Mean time to process progression depended on extent of debulking. Following suboptimal debulking in study group, it was 1.4 month (n = 29), in control group — 2.1 months (n = 48) (р = 0.67); where optimal debulking was performed, the value made 22.1 months (n = 63) and 4.3 months (n = 32), respectively (р < 0.05). The best result was recorded in 16 patients: they had clinical remission for 32 months following optimal debulking with hyperthermic intraperitoneal chemoperfusion and platinum-containing chemotherapy.

Analysis of five-year survival rate demonstrated that in study group where optimal debulking was performed, the value was 20.5%, while in control group it was up to 4.3% (p < 0.05). Sub-optimal debulking resulted in constantly unsatisfactory results.

Conclusion. It is likely that in good time HIPEC for chemical debulking will be routinely used for primary and/or recurring OC. Although this method has not been thoroughly studied in this type of malignancies, it can be considered rational.

Contribution: Guseinov, K.D. — clinical data for the study including surgical treatment of patients, data analysis, manuscript preparation, thematic publications reviewing; Kireeva, G.S., Yakovleva, M.G., Shikhzadaeva M.G. — acquisition of clinical data for the study including surgical treatment of patients, data analysis, thematic publications reviewing; Berlev, I.V., Belyaev, A.M., Urmancheeva, A.F., Gorodnova, T.V. — acquisition of clinical data for the study including surgical treatment of patients, data analysis.

Conflict of interest: The authors declare that they do not have any conflict of interests.

Received: 20.12.2019
Accepted: 23.12.2019

K.D. Guseinov (Corresponding author) — National Medical Scientific Centre of Oncology named after N.N. Petrov of the Ministry of Public Health of Russia; 68 Leningradskaya Str., Vil. Pesochnyy, St. Petersburg, Russian Federation 197758. E-mail: 9446312@gmail.com

I.V. Berlev — National Medical Scientific Centre of Oncology named after N.N. Petrov of the Ministry of Public Health of Russia; 68 Leningradskaya Str., Vil. Pesochnyy, St. Petersburg, Russian Federation 197758. ORCID: http://orcid.org/0000-0001-6937-2740. E-mail: iberlev@gmail.com

A.M. Belyaev — National Medical Scientific Centre of Oncology named after N.N. Petrov of the Ministry of Public Health of Russia; 68 Leningradskaya Str., Vil. Pesochnyy, St. Petersburg, Russian Federation 197758. eLIBRARY.RU SPIN: 9445-9473. E-mail: oncl@rion.spb.ru

A.F. Urmancheeva — National Medical Scientific Centre of Oncology named after N.N. Petrov of the Ministry of Public Health of Russia; 68 Leningradskaya Str., Vil. Pesochnyy, St. Petersburg, Russian Federation 197758. eLIBRARY.RU SPIN: 4169-6011. E-mail: adaurm47mail.ru

T.V. Gorodnova — National Medical Scientific Centre of Oncology named after N.N. Petrov of the Ministry of Public Health of Russia; 68 Leningradskaya Str., Vil. Pesochnyy, St. Petersburg, Russian Federation 197758. eLIBRARY.RU SPIN: 2661-9106. E-mail: t.gorodnova@mail.ru

G.S. Kireeva — National Medical Scientific Centre of Oncology named after N.N. Petrov of the Ministry of Public Health of Russia; 68 Leningradskaya Str., Vil. Pesochnyy, St. Petersburg, Russian Federation 197758. eLIBRARY.RU SPIN: 5643-6973. E-mail: oncl@rion.spb.ru

M.G. Yakovleva — National Medical Scientific Centre of Oncology named after N.N. Petrov of the Ministry of Public Health of Russia; 68 Leningradskaya Str., Vil. Pesochnyy, St. Petersburg, Russian Federation 197758.

M.G. Shikhzadaeva — National Medical Scientific Centre of Oncology named after N.N. Petrov of the Ministry of Public Health of Russia; 68 Leningradskaya Str., Vil. Pesochnyy, St. Petersburg, Russian Federation 197758.

Доктор.ру

Table 1
Characteristics of patients with recurrent ovarian carcinoma

t12_1.jpg

Fig. 1. Drainage arrangement diagram

ris12_1.jpg

 

Fig. 2 Laparotomy wound with drainage. Here and below photos: Courtesy of the authors

ris12_2.jpg

Fig. 3. Thermostatic water bath LOIP LB-200

ris12_3.jpg

Fig. 4. Blood pump

ris12_4.jpg

Table 2
Extent of surgery in recurrent ovarian carcinoma, n (%)

t12_2.jpg

Table 3
Description of complications, n (%)

t12_3.jpg

Fig. 5 Five-year survival rate in patients after debulking operation

ris12_5.jpg

4 February 11:03
LITERATURE
  1. Kaprin A.D., Starinskiy V.V., Petrova G.V., eds. Cancer aid to patients in Russia in 2018. M.: Herzen Scientific and Research Institute of Oncology; 2019. 206 p. (in Russian)
  2. Urmancheeva A.F., Kutusheva G.F., Ulrikh E.A. Ovarian tumours: clinical presentation, diagnosis and treatment. SPb.; 2012. 66 p. (in Russian)
  3. Lu Z., Wang J., Wientjes G.M., Au J. Intraperitoneal therapy for peritoneal cancer. Future Oncol. 2010; 6(10): 1625–41. DOI: 10.2217/fon.10.100
  4. Dedrick R.L. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin. Oncol. 1985; 12(3 suppl.4): S1–6.
  5. Miyagi Y., Fujiwara K., Kigawa J., Itamochi H., Nagao S., Aotani E. et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin — a Sankai Gynecology Study Group (SGSG) study. Gynecol. Oncol. 2005; 99(3): 591–6. DOI: 10.1016/j.ygyno.2005.06.055
  6. Wright A.A., Cronin A., Milne D.E., Bookman M.A., Burger R.A., Cohn D.E. et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J. Clin. Oncol. 2015; 33(26): 2841–7. DOI: 10.1200/JCO.2015.61.4776
  7. Herzog T.J. The role of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer: hope or hoax? Ann. Surg. Oncol. 2012; 19(13): 3998–4000. DOI: 10.1245/s10434-012-2521-1
  8. Amanov S.B., Shanazarov N.A., Privalov A.V. Hyperthermic intraperitoneal chemotherapy in combined therapy of recurrent malignancies and abdomen canceromatosis. “Modern problems of science and education”. Scientific review. Medical science. 2014; 1: 26–7. (in Russian)
  9. Rukhlyada N.V., Bagnenko S.F., Grinev M.V., Belyaev A.M. Management of non-gynaecologic abdomen canceromatosis. Grekov's Bulletin of Surgery. 2002; 161(6): 94–9. (in Russian)
  10. Hotouras A., Desai D., Bhan C., Murphy J., Lampe B., Sugarbaker P.H. Heated intraperitoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review. Int. J. Gynecol. Cancer. 2016; 26(4): 661–70. DOI: 10.1097/IGC.0000000000000664
  11. Ferron G., Simon L., Guyon F., Glehen O., Goere D., Elias D. et al. Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): a French multicentric survey. Eur. J. Surg. Oncol. 2015; 41(10): 1361–7. DOI: 10.1016/j.ejso.2015.07.012
  12. Fagotti A., Costantini B., Petrillo M., Vizzielli G., Fanfani F., Margariti P.A. et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol. Oncol. 2012; 127(3): 502–5. DOI: 10.1016/j.ygyno.2012.09.020
  13. Le Brun J.F., Campion L., Berton-Rigaud D., Lorimier G., Marchal F., Ferron G. et al. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study. Ann. Surg. Oncol. 2014; 21(11): 3621–7.
  14. Spiliotis J., Halkia E., Lianos E., Kalantzi N., Grivas A., Efstathiou E. et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann. Surg. Oncol. 2015; 22(5): 1570–5. DOI: 10.1245/s10434-014-4157-9
Новости мировой медицины! Свежие статьи из журнала! Будьте в курсе!

Похожие статьи

Similar article
19 April 00:00, Interview
Interview
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)
19 April 00:00, Paediatrics
A.V. Aksenov, E.A. Ivanovskaya
Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)

News